FDA warns of serious blood disorder resulting from abuse of Opana ER

Article

FDA has warned patients of thrombotic thrombocytopenic purpura (TTP), a serious blood disorder, resulting from misuse of oxymorphone hydrochloride extended-release tablets (Opana ER, Endo).

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.